1
|
Jia F, Wang J, Peng J, Zhao P, Kong Z, Wang K, Yan W, Wang R. The in vitro, in vivo antifungal activity and the action mode of Jelleine-I against Candida species. Amino Acids 2017; 50:229-239. [PMID: 29101485 DOI: 10.1007/s00726-017-2507-1] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2017] [Accepted: 10/24/2017] [Indexed: 11/28/2022]
Abstract
Recently, the mortality of life-threatening fungal infections increased dramatically. However, there are few antifungals existed. Antimicrobial peptides (AMPs) as promising antifungal candidates have attracted much attention. Here, we present a small antimicrobial peptide Jelleine-I that had potent in vitro and in vivo antifungal activity. Negligible hemolytic activity and in vivo toxicity were observed. Selectivity index (SI) of Jelleine-I is at least 4.6 times higher than amphotericin B. Jelleine-I could increase the production of cellular ROS and bind with genome DNA. This may contribute to its antifungal activity. Furthermore, drug resistance is not induced when the fungal cells were repeatedly treated by Jelleine-I. In conclusion, our results suggest that Jelleine-I may have the potential to be developed as a novel antifungal agent.
Collapse
Affiliation(s)
- Fengjing Jia
- Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences, School of Life Sciences, Lanzhou University, 222 Tian Shui South Road, Lanzhou, 730000, People's Republic of China
| | - Jiayi Wang
- Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences, School of Life Sciences, Lanzhou University, 222 Tian Shui South Road, Lanzhou, 730000, People's Republic of China
| | - Jinxiu Peng
- Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences, School of Life Sciences, Lanzhou University, 222 Tian Shui South Road, Lanzhou, 730000, People's Republic of China
| | - Ping Zhao
- Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences, School of Life Sciences, Lanzhou University, 222 Tian Shui South Road, Lanzhou, 730000, People's Republic of China
| | - Ziqing Kong
- Institute of Food Safety, State Key Laboratory Base of Food Quality and Safety, Ministry of Science and Technology, Jiangsu Academy of Agricultural Sciences, Nanjing, 210014, China
| | - Kairong Wang
- Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences, School of Life Sciences, Lanzhou University, 222 Tian Shui South Road, Lanzhou, 730000, People's Republic of China.
| | - Wenjin Yan
- Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences, School of Life Sciences, Lanzhou University, 222 Tian Shui South Road, Lanzhou, 730000, People's Republic of China.
| | - Rui Wang
- Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences, School of Life Sciences, Lanzhou University, 222 Tian Shui South Road, Lanzhou, 730000, People's Republic of China.
| |
Collapse
|
2
|
Tahmaz Y, Çevikbaş A, Gürer ÜS, Gürbüz B, Çevikbaş U. Investigation of chronotherapeutic effects of amphotericin B administered to mice infected with Candida albicans. BIOL RHYTHM RES 2013. [DOI: 10.1080/09291016.2011.652861] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
3
|
MacCallum DM, Odds FC. Need for early antifungal treatment confirmed in experimental disseminated Candida albicans infection. Antimicrob Agents Chemother 2005; 48:4911-4. [PMID: 15561880 PMCID: PMC529222 DOI: 10.1128/aac.48.12.4911-4914.2004] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Groups of mice infected intravenously with Candida albicans were treated intraperitoneally with amphotericin B, caspofungin, or fluconazole, starting at intervals before and after challenge. Survival was longest and tissue burdens were most reduced with early treatment, and survival times fell proportionately as treatment was delayed, reinforcing clinical recommendations for the earliest possible initiation of antifungal therapy.
Collapse
Affiliation(s)
- Donna M MacCallum
- Aberdeen Fungal Group, School of Medical Sciences, Institute of Medical Sciences, Aberdeen, United Kingdom
| | | |
Collapse
|
4
|
Abstract
Major developments in research into the azole class of antifungal agents during the 1990s have provided expanded options for the treatment of many opportunistic and endemic fungal infections. Fluconazole and itraconazole have proved to be safer than both amphotericin B and ketoconazole. Despite these advances, serious fungal infections remain difficult to treat, and resistance to the available drugs is emerging. This review describes present and future uses of the currently available azole antifungal agents in the treatment of systemic and superficial fungal infections and provides a brief overview of the current status of in vitro susceptibility testing and the growing problem of clinical resistance to the azoles. Use of the currently available azoles in combination with other antifungal agents with different mechanisms of action is likely to provide enhanced efficacy. Detailed information on some of the second-generation triazoles being developed to provide extended coverage of opportunistic, endemic, and emerging fungal pathogens, as well as those in which resistance to older agents is becoming problematic, is provided.
Collapse
Affiliation(s)
- D J Sheehan
- Pfizer Pharmaceuticals Group, Pfizer Inc., New York, New York 10017-5755, USA.
| | | | | |
Collapse
|
5
|
Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. ADVANCES IN PHARMACOLOGY (SAN DIEGO, CALIF.) 1998; 44:343-500. [PMID: 9547888 DOI: 10.1016/s1054-3589(08)60129-5] [Citation(s) in RCA: 288] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- A H Groll
- Immunocompromised Host Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
| | | | | |
Collapse
|